These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
386 related articles for article (PubMed ID: 24173541)
1. Preclinical activity profile and therapeutic efficacy of the HSP90 inhibitor ganetespib in triple-negative breast cancer. Proia DA; Zhang C; Sequeira M; Jimenez JP; He S; Spector N; Shapiro GI; Tolaney S; Nagai M; Acquaviva J; Smith DL; Sang J; Bates RC; El-Hariry I Clin Cancer Res; 2014 Jan; 20(2):413-24. PubMed ID: 24173541 [TBL] [Abstract][Full Text] [Related]
2. Targeted inhibition of Hsp90 by ganetespib is effective across a broad spectrum of breast cancer subtypes. Friedland JC; Smith DL; Sang J; Acquaviva J; He S; Zhang C; Proia DA Invest New Drugs; 2014 Feb; 32(1):14-24. PubMed ID: 23686707 [TBL] [Abstract][Full Text] [Related]
3. Hsp90 Inhibition Results in Glucocorticoid Receptor Degradation in Association with Increased Sensitivity to Paclitaxel in Triple-Negative Breast Cancer. Agyeman AS; Jun WJ; Proia DA; Kim CR; Skor MN; Kocherginsky M; Conzen SD Horm Cancer; 2016 Apr; 7(2):114-26. PubMed ID: 26858237 [TBL] [Abstract][Full Text] [Related]
4. Ganetespib blocks HIF-1 activity and inhibits tumor growth, vascularization, stem cell maintenance, invasion, and metastasis in orthotopic mouse models of triple-negative breast cancer. Xiang L; Gilkes DM; Chaturvedi P; Luo W; Hu H; Takano N; Liang H; Semenza GL J Mol Med (Berl); 2014 Feb; 92(2):151-64. PubMed ID: 24248265 [TBL] [Abstract][Full Text] [Related]
5. Targeting the Janus-activated kinase-2-STAT3 signalling pathway in pancreatic cancer using the HSP90 inhibitor ganetespib. Nagaraju GP; Mezina A; Shaib WL; Landry J; El-Rayes BF Eur J Cancer; 2016 Jan; 52():109-19. PubMed ID: 26682870 [TBL] [Abstract][Full Text] [Related]
6. The HSP90 inhibitor ganetespib has chemosensitizer and radiosensitizer activity in colorectal cancer. He S; Smith DL; Sequeira M; Sang J; Bates RC; Proia DA Invest New Drugs; 2014 Aug; 32(4):577-86. PubMed ID: 24682747 [TBL] [Abstract][Full Text] [Related]
7. Ganetespib overcomes resistance to PARP inhibitors in breast cancer by targeting core proteins in the DNA repair machinery. Jiang J; Lu Y; Li Z; Li L; Niu D; Xu W; Liu J; Fu L; Zhou Z; Gu Y; Xia F Invest New Drugs; 2017 Jun; 35(3):251-259. PubMed ID: 28111726 [TBL] [Abstract][Full Text] [Related]
8. Ganetespib and HSP90: translating preclinical hypotheses into clinical promise. Proia DA; Bates RC Cancer Res; 2014 Mar; 74(5):1294-300. PubMed ID: 24556722 [TBL] [Abstract][Full Text] [Related]
9. Ganetespib (STA-9090), a nongeldanamycin HSP90 inhibitor, has potent antitumor activity in in vitro and in vivo models of non-small cell lung cancer. Shimamura T; Perera SA; Foley KP; Sang J; Rodig SJ; Inoue T; Chen L; Li D; Carretero J; Li YC; Sinha P; Carey CD; Borgman CL; Jimenez JP; Meyerson M; Ying W; Barsoum J; Wong KK; Shapiro GI Clin Cancer Res; 2012 Sep; 18(18):4973-85. PubMed ID: 22806877 [TBL] [Abstract][Full Text] [Related]
10. Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy. Ying W; Du Z; Sun L; Foley KP; Proia DA; Blackman RK; Zhou D; Inoue T; Tatsuta N; Sang J; Ye S; Acquaviva J; Ogawa LS; Wada Y; Barsoum J; Koya K Mol Cancer Ther; 2012 Feb; 11(2):475-84. PubMed ID: 22144665 [TBL] [Abstract][Full Text] [Related]
11. mTOR inhibition potentiates HSP90 inhibitor activity via cessation of HSP synthesis. Acquaviva J; He S; Sang J; Smith DL; Sequeira M; Zhang C; Bates RC; Proia DA Mol Cancer Res; 2014 May; 12(5):703-13. PubMed ID: 24554781 [TBL] [Abstract][Full Text] [Related]
12. HSP-90 inhibitor ganetespib is synergistic with doxorubicin in small cell lung cancer. Lai CH; Park KS; Lee DH; Alberobello AT; Raffeld M; Pierobon M; Pin E; Petricoin Iii EF; Wang Y; Giaccone G Oncogene; 2014 Oct; 33(40):4867-76. PubMed ID: 24166505 [TBL] [Abstract][Full Text] [Related]
13. Hsp90 Inhibitor Ganetespib Sensitizes Non-Small Cell Lung Cancer to Radiation but Has Variable Effects with Chemoradiation. Wang Y; Liu H; Diao L; Potter A; Zhang J; Qiao Y; Wang J; Proia DA; Tailor R; Komaki R; Lin SH Clin Cancer Res; 2016 Dec; 22(23):5876-5886. PubMed ID: 27354472 [TBL] [Abstract][Full Text] [Related]
14. Strong antitumor synergy between DNA crosslinking and HSP90 inhibition causes massive premitotic DNA fragmentation in ovarian cancer cells. Kramer D; Stark N; Schulz-Heddergott R; Erytch N; Edmunds S; Roßmann L; Bastians H; Concin N; Moll UM; Dobbelstein M Cell Death Differ; 2017 Feb; 24(2):300-316. PubMed ID: 27834954 [TBL] [Abstract][Full Text] [Related]
15. Heat shock protein 90 (HSP90) is overexpressed in p16-negative oropharyngeal squamous cell carcinoma, and its inhibition in vitro potentiates the effects of chemoradiation. Patel K; Wen J; Magliocca K; Muller S; Liu Y; Chen ZG; Saba N; Diaz R Cancer Chemother Pharmacol; 2014 Nov; 74(5):1015-22. PubMed ID: 25205430 [TBL] [Abstract][Full Text] [Related]
16. Overcoming acquired resistance to HSP90 inhibition by targeting JAK-STAT signalling in triple-negative breast cancer. Mumin NH; Drobnitzky N; Patel A; Lourenco LM; Cahill FF; Jiang Y; Kong A; Ryan AJ BMC Cancer; 2019 Jan; 19(1):102. PubMed ID: 30678647 [TBL] [Abstract][Full Text] [Related]
17. Efficacy of an HSP90 inhibitor, ganetespib, in preclinical thyroid cancer models. Lin SF; Lin JD; Hsueh C; Chou TC; Yeh CN; Chen MH; Wong RJ Oncotarget; 2017 Jun; 8(25):41294-41304. PubMed ID: 28476040 [TBL] [Abstract][Full Text] [Related]
18. Targeting heat-shock protein 90 with ganetespib for molecularly targeted therapy of gastric cancer. Liu H; Lu J; Hua Y; Zhang P; Liang Z; Ruan L; Lian C; Shi H; Chen K; Tu Z Cell Death Dis; 2015 Jan; 6(1):e1595. PubMed ID: 25590805 [TBL] [Abstract][Full Text] [Related]
19. Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models. Proia DA; Sang J; He S; Smith DL; Sequeira M; Zhang C; Liu Y; Ye S; Zhou D; Blackman RK; Foley KP; Koya K; Wada Y Invest New Drugs; 2012 Dec; 30(6):2201-9. PubMed ID: 22227828 [TBL] [Abstract][Full Text] [Related]
20. Ganetespib targets multiple levels of the receptor tyrosine kinase signaling cascade and preferentially inhibits ErbB2-overexpressing breast cancer cells. Lee H; Saini N; Howard EW; Parris AB; Ma Z; Zhao Q; Zhao M; Liu B; Edgerton SM; Thor AD; Yang X Sci Rep; 2018 May; 8(1):6829. PubMed ID: 29717218 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]